Table 1.
Demographics of patients by first-, second- and third-line ART regimen
| First-line regimen (n= 16,962) | Second-line regimen (n= 4,336) | Third-line regimen (n= 1,135) | |
|---|---|---|---|
|
| |||
| Year of ART initiation | |||
| 2003–2005 | 2,874 (17) | 274 (6) | 72 (6) |
| 2006–2009 | 6,248 (37) | 1,473 (34) | 381 (34) |
| 2010–2013 | 7,840 (46) | 2,589 (60) | 682 (60) |
| Age at ART initiation | |||
| ≤30 years | 4,328 (25) | 630 (14) | 139 (12) |
| 31–40 years | 7,648 (45) | 1,981 (46) | 482 (42) |
| 41–50 years | 3,335 (20) | 1,161 (27) | 361 (32) |
| 51+ years | 1,651 (10) | 564 (13) | 153 (14) |
| Median (IQR) | 36 (30–42) | 38 (33–45) | 40 (34–46) |
| Sex | |||
| Male | 11,637 (69) | 3,155 (73) | 843 (74) |
| Female | 5,309 (31) | 1,176 (27) | 292 (26) |
| Transgender | 16 (<1) | 5 (<0.2) | 0 (-) |
| Mode of HIV exposure | |||
| Heterosexual | 13,549 (80) | 3,445 (79) | 917 (81) |
| Homosexual | 1,300 (8) | 407 (9) | 102 (9) |
| Injecting drug user | 780 (4) | 132 (3) | 28 (2) |
| Other/Unknown | 1,333 (8) | 352 (8) | 88 (8) |
| Hepatitis B (surface antigen) co-infection (ever) | |||
| Positive | 886 (5) | 227 (5) | 42 (4) |
| Negative | 8,510 (50) | 2,192 (51) | 562 (49) |
| Not tested | 7,566 (45) | 1,917 (44) | 531 (47) |
| Hepatitis C (antibody) co-infection (ever) | |||
| Positive | 1,027 (6) | 187 (4) | 40 (3) |
| Negative | 7,456 (44) | 1,924 (45) | 464 (41) |
| Not tested | 8,479 (50) | 2,225 (51) | 631 (56) |
| CD4+ T-cell count at ART initiation | |||
| ≤50 cells/μl | 3,623 (21) | 532 (12) | 149 (13) |
| 51–100 cells/μl | 2,291 (13) | 424 (10) | 106 (9) |
| 101–200 cells/μl | 3,848 (23) | 802 (18) | 199 (18) |
| >200 cells/μl | 4,692 (28) | 1,844 (43) | 485 (43) |
| Not tested | 2,508 (15) | 734 (17) | 196 (17) |
| Median (IQR) | 136 (50–231) | 207 (93–371) | 214 (88–390) |
| HIV viral load at ART initiation | |||
| <1,000 copies/ml | 141 (1) | 618 (14) | 196 (17) |
| 1,000–10,000 copies/ml | 310 (2) | 137 (3) | 34 (3) |
| ≥10,001 copies/ml | 3,147 (18) | 692 (16) | 172 (15) |
| Not tested | 13,364 (79) | 2,889 (67) | 733 (65) |
| Median (IQR) | 110,782 (30,500–372,000) | 6,080 (49–106,000) | 1,628 (49–103,046) |
| ART regimen | |||
| NRTI+NNRTI | 16,030 (94) | 2,287 (53) | 412 (36) |
| NRTI+PI | 819 (5) | 1,504 (35) | 509 (45) |
| Other | 113 (1) | 545 (12) | 214 (19) |
| Previous mono/dual therapy | |||
| No | 16,365 (96) | 4,061 (94) | 1,022 (90) |
| Yes | 597 (4) | 275 (6) | 113 (10) |
Data are n (%) unless otherwise indicated. ART, antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.